SCHEMBL5413441

SCHEMBL5413441

COC1CCCC(CN2C(=O)c3ccccc3C2=O)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 4/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ACHE P22303 1/20 0.43
TRPA1 O75762 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 4/20 0.40
HPGD P15428 3/20 0.40
PLIN1 O60240 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
PLIN5 Q00G26 1/20 0.40
ABHD5 Q8WTS1 1/20 0.40
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
GAA P10253 2/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5413443 1.00 CYP1B1 (0.46) CYP1B1CYP1A2CYP2C9CYP2C19ACHE
SCHEMBL5413446 1.00 CYP1B1 (0.46) CYP1B1CYP1A2CYP2C9CYP2C19ACHE
SCHEMBL16513487 0.83 CYP1B1 (0.43) CYP1B1CYP1A2CYP2C9CYP2C19TRPA1
SCHEMBL17933679 0.81 CYP1B1 (0.49) CYP1B1CYP1A2CYP2C9CYP2C19ACHE
SCHEMBL4294530 0.80 ALDH1A1 (0.39) CYP1B1CYP1A2CYP2C9CYP2C19ACHE
SCHEMBL4294531 0.80 ALDH1A1 (0.39) CYP1B1CYP1A2CYP2C9CYP2C19ACHE
SCHEMBL4294532 0.80 ALDH1A1 (0.39) CYP1B1CYP1A2CYP2C9CYP2C19ACHE
SCHEMBL5404942 0.78 CYP1B1 (0.49) CYP1B1CYP1A2CYP2C9CYP2C19ACHE
SCHEMBL5404937 0.78 CYP1B1 (0.49) CYP1B1CYP1A2CYP2C9CYP2C19ACHE
SCHEMBL5416078 0.78 CYP1B1 (0.49) CYP1B1CYP1A2CYP2C9CYP2C19ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 US disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA CYP1B1 921/4885CYP1A2 2102/4885CYP2C9 3451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.